HAEMONETICS CORPORATION (NYSE:HAE) Files An 8-K Submission of Matters to a Vote of Security HoldersITEM 5.07Submission of Matters to a Vote of Security Holders.
The Annual Meeting of Shareholders of Haemonetics Corporation (the "Company") was held on Thursday, July 27, 2017. At the Meeting:
|
1. |
Christopher Simon and Charles Dockendorff were elected to serve as directors of the Company; |
|
2. |
An advisory vote regarding the compensation of the Company's Named Officers was approved; |
|
3. |
An advisory vote on the frequency of future advisory votes of our Named Offices was approved for one (1) year; |
|
4. |
Shareholder proposal to recommend changes to certain voting requirements was approved; and |
|
5. |
The selection of Ernst & Young LLP to serve as the independent registered public accounting firm of the Company for fiscal year 2018 was ratified. |
Below are the number of votes cast For or Against, the number of Abstentions, the number of votes Withheld and the number of broker Non-Votes:
1. Election of Directors:
|
Director |
Votes For |
Withheld |
Non-Vote |
|
Christopher Simon |
47,803,770 |
474,278 |
1,687,791 |
|
Charles J. Dockendorff |
42,854,663 |
5,423,385 |
1,687,791 |
2. Advisory vote regarding the compensation of the Company's Named Officers:
|
Votes For |
Votes Against |
Abstain |
Non-Vote |
|
47,874,905 |
379,378 |
23,765 |
1,687,791 |
3. Advisory vote on frequency of future advisory votes on the compensation of the Company's Named Officers:
|
One Year |
Two Years |
Three Years |
Abstain |
Non-Vote |
|
40,927,606 |
13,447 |
7,321,664 |
15,331 |
1,687,791 |
4. Shareholder Proposal regarding changes to certain voting requirements:
|
Votes For |
Votes Against |
Abstain |
Non-Vote |
|
38,562,997 |
7,409,594 |
2,305,457 |
1,687,791 |
5. Ratification of appointment of Ernst & Young, LLP as the Company's independent registered public accounting firm for the fiscal year ending March 31, 2018:
|
Votes For |
Votes Against |
Abstain |
Non-Vote |
|
49,762,695 |
198,448 |
4,696 |
Consistent with the stated preference of a majority of the Company’s shareholders, the Board determined that it will hold an annual advisory vote on the compensation of the Company’s Named Officers every year until the next required vote on the frequency of shareholder votes on compensation of Named Officers, which will occur no later than Company’s annual meeting of shareholders in 2023.
About HAEMONETICS CORPORATION (NYSE:HAE)
Haemonetics Corporation (Haemonetics) is a healthcare company. The Company provides various products to customers involved in the processing, handling and analysis of blood. The Company’s segments include Japan, EMEA, North America Plasma and All Other. Haemonetics provides plasma collection systems and software, which enable plasma fractionators to make pharmaceuticals. The Company enables plasma collection customers to source from it a range of products necessary for plasma collection and storage, including PCS brand plasma collection equipment and disposables, plasma collection containers and intravenous solutions, such as saline. Haemonetics offers automated blood component and manual whole blood collection systems to blood collection centers to collect blood products. The Company offers a range of blood management solutions. The Company has a suite of integrated software solutions, which include solutions for blood drive planning and blood collection.
